Aelis Farma SA (AELIS) - Total Liabilities
Based on the latest financial reports, Aelis Farma SA (AELIS) has total liabilities worth €9.46 Million EUR (≈ $11.07 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Aelis Farma SA (AELIS) equity growth momentum to track the company's year-over-year net asset growth rate.
Aelis Farma SA - Total Liabilities Trend (2017–2024)
This chart illustrates how Aelis Farma SA's total liabilities have evolved over time, based on quarterly financial data. See AELIS free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Aelis Farma SA Competitors by Total Liabilities
The table below lists competitors of Aelis Farma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Equus Total Return Closed Fund
NYSE:EQS
|
USA | $4.77 Million |
|
Modernland Realty Ltd Tbk
JK:MDLN
|
Indonesia | Rp9.42 Trillion |
|
Hanwha Investment&Securities Co Ltd Pref
KO:003535
|
Korea | ₩14.19 Trillion |
|
Riversgold Ltd
AU:RGL
|
Australia | AU$233.64K |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
Malaysia | RM37.63 Million |
|
Marpai Inc
NASDAQ:MRAI
|
USA | $46.16 Million |
|
Capital Point
TA:CPTP
|
Israel | ILA26.64 Million |
|
Raspberry Pi Holdings PLC
LSE:RPI
|
UK | GBX67.51 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Aelis Farma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aelis Farma SA market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.43 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aelis Farma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aelis Farma SA (2017–2024)
The table below shows the annual total liabilities of Aelis Farma SA from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.59 Million ≈ $11.21 Million |
-26.68% |
| 2023-12-31 | €13.08 Million ≈ $15.29 Million |
-32.67% |
| 2022-12-31 | €19.43 Million ≈ $22.71 Million |
-29.13% |
| 2021-12-31 | €27.41 Million ≈ $32.05 Million |
+255.62% |
| 2020-12-31 | €7.71 Million ≈ $9.01 Million |
+28.14% |
| 2019-12-31 | €6.02 Million ≈ $7.03 Million |
+53.59% |
| 2018-12-31 | €3.92 Million ≈ $4.58 Million |
-14.90% |
| 2017-12-31 | €4.60 Million ≈ $5.38 Million |
-- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more